|
1) D'Haens G, Baert F, van Assche G, et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet. 2008; 371: 660-7
|
|
|
|
2) Munkholm P, Langholz E, Davidsen M, et al. Intestinal cancer risk and mortality in patients with Crohn's disease. Gastroenterology. 1993; 105: 1716-23
|
|
|
|
|
|
3) Faubion W, Loftus E, Harmsen W, et al. The Natural History of Corticosteroid Therapy for Inflammatory Bowel Disease: A Population-Based Study. Gastroenterology. 2001; 121: 255-66
|
|
|
|
|
|
4) Cosnes J, Nion-Larmurier I, Beaugerie L, et al. Impact of the increasing use of immunosuppressants in Crohn's disease on the need for intestinal surgery. Gut. 2005; 54: 237-41
|
|
|
|
|
|
5) Cosnes J, Cattan S, Blain A, et al. Long-term evolution of disease behavior of Crohn's disease. Inflammatory Bowel Diseases. 2002; 8: 244-50
|
|
|
|
|
|
6) Hyams J, Crandall W, Kugathasan S, et al. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children. Gastroenterology. 2007; 132: 863-73
|
|
|
|
|
|
7) Schreiber S, Khaliq-Kareemi M, Lawrance I, et al. Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med. 2007; 357: 239-50
|
|
|
|
|
|
8) Loftus E, Silverstein M, Sandborn W, et al. Crohn's disease in Olmsted County, Minnesota, 1940-1993: Incidence, prevalence, and survival. Gastroenterology. 1998; 114: 1161-8
|
|
|
|
|
|
9) Rurgeerts P, Feagan B, Lichtenstein G, et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology. 2004; 126: 402-13
|
|
|
|
|
|
10) Lees C, Ironside J, Wallace W, et al. Resolution of nonsmall-cell lung cancer after withdrawal of anti-TNF therapy. N Engl J Med. 2008; 359: 320-1
|
|
|
|
|